About Us

Transparency Life Sciences, the first all-digital clinical development services company, harnesses crowdsourcing and mobile health technology to advance biopharma drug candidates through clinical trials with unprecedented patient relevance and efficiency.

The TLS model is highly scalable and is designed to increase current industry margins of a wasteful process that often collects irrelevant data. Drug companies will outsource an estimated $38B of clinical trial services to CROs by 2020, with a CAGR of 9-10%. Yet this robust growth masks significant customer dissatisfaction. Sponsors want clinical trials to be better-designed, technologically advanced, patient-centric, and significantly less expensive, yet change has been limited by an inability to see beyond the current outmoded, site-centric model.

As a consequence, only select compounds are being developed in humans, leaving many potential important therapies untested in clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation, significantly improving the quality of clinical trials while reducing their cost.

TLS Response

TLS addresses the clinical trials market opportunity with an end-to-end digital rethink built on three pillars:

TLS’s Protocol Builder enables patients, physicians, researchers and other stakeholders to co-design clinical trials through crowdsourcing, and produce protocols more relevant to patient needs and clinical practice.

site.TLS virtual trial and data platform leverages advances in mobile health and cloud technology to execute informative, cost-effective clinical studies that are far more convenient for patients. site.TLS’s flexible architecture adapts to encompass a broad range of protocol designs, from trials involving a single virtual site to those with hospital/clinic site requirements.

Transparency throughout the development process builds credibility with diverse stakeholders.

TLS’s comprehensive approach integrates these three components to create a unique, 21st century approach to drug development.